SPOTLIGHT -
Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.
Bipartisan proposal introduced in US House to address children's vision impairment
ROP: Treating and preventing blindness in preterm babies
Study: Pediatric eye care deserts are a growing issue
Managing a changing landscape of IRD pediatric cases
Intra-anterior chamber injection of ranibizumab a potentially relatively safe treatment for advanced pediatric vitreoretinal diseases
Partners collaborate on integration of AI-supported ROP telemedicine globally